Effect of amantadine on L-2-14C-dopa metabolism in parkinsonism

Abstract A metabolic study of the effects of amantadine hydrochloride on the fate of orally administered L-2- 14 C-dopa is described in three subjects with Parkinson's disease. Serum and urine distribution of radioactivity were determined in catecholamine, dopa, methoxydopa, and phenol carboxylic acid fractions prior to and after the administration of amantadine 100 mg daily for 4 weeks. Amantadine moderately decreased serum and urinary radioactivity during the first 2 hrs. Further, amantadine administration markedly decreased the urinary, but not serum, catecholamine fraction. Concomitantly, a two fold rise in urinary phenol carboxylic acids fraction from base line values was noted. It is concluded that amantadine may decrease extracerebral metabolism of levodopa and reduce the extent of its metabolism to its catecholamine metabolites.